Research Topics
| Harriet KlugerSummaryAffiliation: Yale University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survivalAaron J Berger
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Cancer Res 63:8103-7. 2003..Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage melanoma...- Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanomaKyle A Divito
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Res 64:8773-7. 2004..These results suggest studies are needed to evaluate the association between quantitative assessment of Bcl-2 expression and response to Bcl-2 targeting therapy toward the goal of improved response rates to these drugs... - Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancerAymen A Elfiky
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States of America
J Transl Med 9:133. 2011..We characterized expression of p85 and p110? PI3K subunits and mTOR in RCC specimens and assessed pharmacologic co-targeting of these molecules in vitro... - Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Jill C Rubinstein
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
J Transl Med 8:67. 2010..Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations... - Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerYasmine Nadler
Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Breast Cancer Res 10:R35. 2008.... - Characterizing disease states from topological properties of transcriptional regulatory networksDavid P Tuck
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
BMC Bioinformatics 7:236. 2006..We analyzed expression datasets from a number of diseased and normal cells, including different types of acute leukemia, and breast cancer with variable clinical outcome... - The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitizationHarriet M Kluger
Department of Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
J Transl Med 5:6. 2007..Targeting XIAP warrants additional investigation as a therapeutic approach for metastatic melanoma... - A phase 2 trial of dasatinib in advanced melanomaHarriet M Kluger
Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Cancer 117:2202-8. 2011..Dasatinib inhibits c-kit, PDGF?R, and EPHA2 and src kinases c-src, c-Yes, Lck, and Fyn. A phase 2 trial of dasatinib in melanoma was conducted to assess response rate (RR), progression-free survival (PFS), and toxicity... - Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray studyHarriet M Kluger
Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Melanoma Res 14:207-10. 2004..Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence... - cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer modelHarriet M Kluger
Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Lab Invest 84:320-31. 2004..These genes provide a basis for further studies of metastatic progression and local invasiveness, and can be evaluated as therapeutic targets... - Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysisHarriet M Kluger
Departments of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Cancer Res 10:173-7. 2004..Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data... - Expression profiling reveals novel pathways in the transformation of melanocytes to melanomasKeith Hoek
Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520-8059, USA
Cancer Res 64:5270-82. 2004..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients... - Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesionsBonnie E Gould Rothberg
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
Mod Pathol 21:1121-9. 2008..80 for distinguishing benign nevi from malignant melanomas. On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions... - Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive diseaseHarriet M Kluger
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
Cancer Res 65:5578-87. 2005.... - Melanoma prognostic model using tissue microarrays and genetic algorithmsBonnie E Gould Rothberg
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
J Clin Oncol 27:5772-80. 2009..Here, we propose a multimarker molecular prognostic assay that can help triage patients at increased risk of recurrence... - High HSP90 expression is associated with decreased survival in breast cancerElah Pick
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
Cancer Res 67:2932-7. 2007..Prospective studies are needed to confirm the prognostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors... - Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcomeAaron J Berger
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Res 64:8767-72. 2004.... - Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancerNicolas Acquavella
Melanoma Program, Yale Cancer Center, Yale New Haven Hospital, 333 Cedar Street, New Haven, CT 06520, USA
J Immunother 31:569-76. 2008..In summary, the twice-daily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators... - Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanomaMary M McCarthy
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 12:3856-63. 2006..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi... - C-Raf is associated with disease progression and cell proliferation in a subset of melanomasLucia B Jilaveanu
Yale Cancer Center and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 15:5704-13. 2009..Although the role of B-Raf in melanoma is well established, little is known about C-Raf. We studied effects of C-Raf knockdown in vitro and assessed expression of C-Raf in a large cohort of melanomas and nevi... - Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenibLucia Jilaveanu
Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 15:1076-85. 2009..We assessed the expression of sorafenib targets in SCP-treated patient specimens and evaluated the association with response and progression-free survival... - Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancerYasmine Nadler
Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Cancer Res 14:4455-62. 2008..We therefore assessed expression of Aurora A and B in breast tumors and studied associations with clinical/pathologic variables... - Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancerMary M McCarthy
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Cancer Res 11:5188-94. 2005..We sought to determine the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in early-stage breast cancer... - Assessing expression of apoptotic markers using large cohort tissue microarraysElah Pick
Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
Methods Mol Biol 414:83-93. 2008.... - Chemotherapy and biologic therapies for melanoma: do they work?Lucia B Jilaveanu
Department of Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
Clin Dermatol 27:614-25. 2009..This contribution summarizes the risks and benefits of older regimens and discusses the newer, targeted therapies... - Phosphatidylinositol-3-kinase as a therapeutic target in melanomaSaadia A Aziz
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Cancer Res 15:3029-36. 2009..We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002... - Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancerMalini Harigopal
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Cancer Res 11:4083-9. 2005..We investigated the relationship between E-cadherin expression in primary invasive ductal tumors and corresponding nodal metastases, and determined the prognostic value of E-cadherin expression in node-positive breast cancer... - Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert
Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Hum Pathol 41:375-84. 2010..Such assessments could assist with evaluation of these molecules as therapeutic targets in melanoma, ultimately facilitating improved selection of patients for treatment... - alphaB-crystallin as a marker of lymph node involvement in breast carcinomaDina Chelouche-Lev
Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:2543-8. 2004.... - Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancerKenneth D Bromberg
Signal Transduction Program, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
Cancer Res 67:8172-9. 2007....
Research Grants
- Predicting Melanoma Response to BAY 43-9006/ChemotherapyHarriet Kluger; Fiscal Year: 2007..We will assess individual markers as well as panels of markers. ..